When it comes to efficient clinical study build, content is king. Most importantly: metadata content. Metadata is the building blocks of your study. It’s the forms, terminologies and datasets you…
aCRFs are a mandatory requirement of the FDA, and therefore a key submission deliverable for any clinical trial. Creating quality annotated case report forms (aCRFs) takes time and attention to…
Nonalcoholic fatty liver disease (NAFLD) is a condition wherein the liver stores excess fat. Nonalcoholic steatohepatitis (NASH) is one type of NAFLD. Individuals with obesity and type 2 diabetes appear…
RADNOR, Pa. — 2024年8月21日 — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:…
Services offered by Certara global market access experts to navigate the new EU HTA Regulation and prepare timely and high quality JCA submissions
Cytokine Release Syndrome Cytokine release syndrome (CRS) is an inflammatory immune reaction that clinically manifests as fever, headache, joint, and muscle pain in mild cases to hypotension, vascular leakage, and…
ウェビナーシリーズ「FDA/EMA 準拠に関する共同ガイドライン – 進化するEU規制への対応」の第2回をどうぞお見逃しなく。こちらよりご登録いただけます。
Many companies in the life sciences industry are slow to adopt new technologies. This is often down to budget restrictions, greater operational burden, and uncertainty with meeting complex regulatory requirements. …
All new and existing drugs should be safe, effective, and efficacious for the treated populations. Pharma companies must maintain this benefit-risk balance throughout the drug lifecycle. The reporting rate of…
© 2025 Certara. All Rights Reserved. | 個人情報保護
